

Association of neutrophil / lymphocyte ratio, platelet / lymphocyte ratio and brachial retinal vein occlusion

Mahmut Atum¹, Isa Yuvaci¹, Selcuk Yaylaci², Ahmed Bilal Genc², Turgay Ucak³, Erdinc Bozkurt⁴, Gursoy Alagoz¹

¹Sakarya University Education and Research Hospital, Department of Ophthalmology, Sakarya, Turkey

²Sakarya University Education and Research Hospital, Department of Internal Medicine, Sakarya, Turkey

³Erzincan Binali Yildirim University, Faculty of Medicine, Department of Ophthalmology, Erzincan, Turkey

⁴Kafkas University, Faculty of Medicine, Department of Ophthalmology, Kars, Turkey

Copyright © 2019 by authors and Annals of Medical Research Publishing Inc.

Abstract

Aim: In this study, we aimed to measure neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) levels in brachial retinal vein occlusion (BRVO) patients and to determine whether there it could be used as a marker for BRVO. Brachial retinal vein occlusion is a serious disease that causes vision loss and is associated with inflammation.

Material and Methods: This retrospective study included 77 patients with BRVO and 69 healthy controls. BRVO was diagnosed with ophthalmic examination. Blood samples were obtained from venous blood and serum neutrophil, lymphocyte, and platelet data of all patients were recorded also, NLR-PLR values were calculated.

Results: Significant difference were not found between the BRVO group and control group with the level of white blood cells (WBC) and platelets ($p>0.05$). Neutrophil count was significantly increased in BRVOs compared to the controls (4.79 ± 1.89 vs 4.02 ± 1.47 , $p=0.007$). Lymphocyte count was significantly decreased in BRVOs compared to the controls. (2.17 ± 0.76 vs 2.52 ± 1.03 , $p=0.022$) NLR was significantly increased in BRVOs compared to the controls. (2.60 ± 2.05 vs 1.74 ± 0.70 , $p=0.001$) Also, PLR was significantly increased in BRVOs compared to the controls. (129.70 ± 68.77 vs 107.96 ± 40.65 , $p=0.023$)

Conclusion: In our study we found that NLR and PLR were significantly increased in BRVOs than in controls.

Keywords: Neutrophil/lymphocyte ratio; platelet/lymphocyte ratio; brachial retinal vein occlusion, retinal vessels.

INTRODUCTION

Diabetic retinopathy is the most common cause of retinal vasculopathy and retinal vein occlusion (RVO) is the second reason (1). According to a prevalence study by Rogers et al, approximately 16.4 million people are affected by RVO. 13.9 million of these people affected by brachial retinal vein occlusion (BRVO) and 2.5 million affected by central retinal vein occlusion (CRVO) and. Also, in all ethnic populations prevalence of BRVO was higher than CRVO (2). RVO usually affects the middle-aged and elderly patient population (3). Several studies have shown that RVO is associated with glaucoma, hypercoagulable conditions and systemic diseases (such as hypertension, diabetes, systemic vascular disease) (4-5). In the pathogenesis of BRVOs, it is known that compression of veins at arteriovenous crossings is the main reason (6). Systemic

and local inflammations are thought to have a serious effect in the etiology of RVO (7). A study of Ross showed that atherosclerosis is a chronic, low-grade inflammatory condition and RVO patients are independently associated with atherosclerosis (8).

Neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR), calculated from hemogram are systemic inflammatory responses. Many different studies published before have shown that NLR and PLR are indicative of systemic inflammation (9-11). Mean platelet volume (MPV) is a parameter that indicates the status of platelets, and MPV is associated with inflammation (12).

In this study, we aimed to measure NLR and PLR in BRVOs and to determine whether there it could be used as a marker for BRVO.

Received: 05.07.2019 Accepted: 16.08.2019 Available online: 21.10.2019

Corresponding Author: Turgay Ucak, Erzincan Binali Yildirim University, Faculty of Medicine, Department of Ophthalmology, Erzincan, Turkey, E-mail: turgayucak@yahoo.com

MATERIAL and METHODS

This study was performed retrospectively in the Sakarya University Third Affiliated Training and Research Hospital Department of Ophthalmology. Data were excluded from the file records of patients who diagnosed with BRVO between January 2016 and August 2018. All subjects underwent complete ophthalmic evaluation of both the eyes, including the best corrected visual acuity, slit-lamp inspection of the anterior segment, applanation tonometry and slit-lamp examination of fundus with 90D Volk lens. Color fundus photographs and fundus fluorescein angiography were performed to the patients and the diagnosis of BRVO was defined accordingly (13).

The study consisted 77 BRVOs and 69 controls. Healthy control patients consisted of patients with presbyopia in ophthalmology outpatient clinic. Age and sex matched in the groups. Also, patients with hypertension (HT) was matched.

Criteria for exclusion were; systemic diseases (such as cardiovascular diseases and diabetes), history of stroke, blood disorders, anemia, renal failure, hepatic disorders, malignancies, and vasculitis. Also, patients with glaucoma and with a history of eye surgery were excluded from the study.

Hemogram parameters of all cases were measured by Cell-DYN 3700 (Cell-DYN 3700, Abbott Diagnostics, Abbott Park, IL, USA) automated hematology analyzer. According to the results of hemogram; neutrophil, lymphocyte and platelet data of all cases were recorded and NLR-PLR values were calculated.

The study was carried out under the ethical principles of the Helsinki Declaration and approved by the Sakarya University Medical School Ethics Committee.

Statistical Analysis

Data analyzed due to the SPSS (17.0, SPSS Inc., Chicago, IL, USA) software program. Numerical data were presented as mean and standard deviation. Comparison of the independent groups was done by parametric Student t test. Cut-off point between BRVO group and control group determined regarding receiver operating characteristic (ROC) curve analysis. According to the cut-off value, sensitivity and specificity values were calculated. The results were evaluated according to 95% confidence interval (CI) and $P < 0.05$ level.

RESULTS

Our study consisted of a total of 146 patients, including 77 patients with BRVO and 69 healthy controls. The BRVO group consisted of 34 male and 43 female patients, and the control group included 31 male and 38 female patients. The mean age of the BRVO group was 59.22 ± 11.98 years and the control group was 56.97 ± 10.78 years. There was no significant difference between BRVO group and control group in terms of gender and age. ($p > 0.05$) (Table 1). In

addition, there was no significant difference between the control group (69 to 18) and BRVO (77 to 26) in terms of the presence of HT. ($p = 0.316$)

No statistically significant difference was found between the BRVO group and the control group in terms of white blood cells and platelet levels ($p > 0.05$). Significantly increased neutrophil count was seemed in BRVOs compared to the controls (4.79 ± 1.89 vs 4.02 ± 1.47 , $p = 0.007$). Significantly decreased lymphocyte count was seemed in BRVOs compared to the controls (2.17 ± 0.76 vs 2.52 ± 1.03 , $p = 0.022$).

NLR was significantly increased in BRVOs compared to the controls (2.60 ± 2.05 vs 1.74 ± 0.70 , $p = 0.001$). Also, PLR was significantly increased in BRVOs compared to the controls (129.70 ± 68.77 vs 107.96 ± 40.65 , $p = 0.023$) (Table 1).

In logistic regression analysis, we found that NLR was an independent indicator of BRVO [odds ratio (OR) = 1.709; 95% CI = 1.146-2.549; $p = 0.009$]. But PLR was not an independent indicator of BRVO. (OR = 1.006; 95% CI = 0.999-1.012; $p = 0.116$).

According to the ROC analysis, the area under curve (AUC) for NLR was 0.645, the cut-off value was 1.775, the sensitivity was 60%, and the specificity was 58%. (95% CI: 0.555-0.734). The AUC for PLR was 0.564, the cut-off value was 109.950, the sensitivity was 55%, and the specificity was 55%. (95% CI: 0.468-0.660) (Figure 1).




Figure 1: ROC curve analysis of NLR and PLR in BRVO patients. NLR was determined to be more sensitive and had a higher rate as a predictor of inflammation compared to PLR. AUC for NLR: 0.645, cut-off value: 1.775, sensitivity: 60%, specificity: 58%. (95% CI: 0.555-0.734). AUC for PLR: 0.564, cut-off value: 109.950, sensitivity: 55%, specificity: 55%. (95% CI: 0.468-0.660)

Table 1. Comparison of the demographic and laboratory findings of BRVOs and controls

	BRVO (n=77)	CONTROL (n=69)	p
Age (y)	59.22±11.984	56.97±10.784	0.237
Sex(M/F)	34/43	31/38	0.926
HT	26	18	0.316
WBC	7.75±2.21	7.38±2.20	0.307
Neutrophil (103/mL)	4.79±1.89	4.02±1.47	0.007
Lymphocyte (103/mL)	2.17±0.76	2.52±1.03	0.022
Platelet (103/mL)	247.25±60.73	242.81±57.31	0.652
NLR	2.60±2.05	1.74±0.70	0.001
PLR	129.70±68.77	107.96±40.65	0.023

BRVO: brachial retinal vein occlusion; M: male; F: female; WBC: white blood cell; NLR: neutrophil/lymphocyte ratio; PLR: platelet/lymphocyte ratio.

ROC: receiver operating characteristic; BRVO: brachial retinal vein occlusion; NLR: neutrophil/lymphocyte ratio; PLR: platelet/ lymphocyte ratio; AUC: area under curve.

DISCUSSION

In this study we found that NLR and PLR were significantly increased in BRVOs and NLR can be used an independent marker for BRVO. According to studies in the literature, this is the first study to investigate the relationship between NLR, PLR and BRVO.

Both systemic and local inflammations are thought to have a serious effect in the etiology of RVO (7). The mechanism of RVO development in systemic inflammation is due to systemic hypercoagulation triggering. In systemic inflammation, levels of many inflammatory chemokines/ cytokines (such as interleukin-1 beta and interleukin-6) are increases and it activates the coagulation. At the same time, these chemokines / cytokines activate pathways that inhibit fibrinolysis (14-16. Noma et al. have shown that local inflammation in the eye can cause RVO formation. He also reported that, patients with RVO had elevated levels of high proinflammatory cytokines/chemokines (such as interleukin-1, interleukin-6 and interleukin-8) in the vitreous fluid (17).

NLR is calculated by dividing the number of neutrophils by the lymphocyte count and is considered a cheap indicator of systemic inflammation. Systemic inflammation typically involves lymphopenia and neutrophilia (18). Gokhan et al showed that NLR was found to be an independent variable for symptomatic carotid artery disease. Also, NLR was higher in symptomatic patients than asymptomatic patients with stroke and transient ischemic attack (19). ($p = < 0.001$) A meta-analysis by Bhat et al. showed that NLR may play a serious role in the diagnosis and prognosis of peripheral vascular diseases (20). In another study performed by Dursun et al. showed that NLR was significantly increased

in RVOs compared to the controls (21). ($p < 0.001$) In our study, NLR was significantly increased in BRVOs than the controls, which may contribute to the pathogenesis of BRVO. Logistic regression analysis showed that NLR is an independent indicator of BRVO.

The PLR is calculated by dividing the number of platelets to lymphocyte count and it is cheap, and giving some information about condition of platelets and white cells. Thrombocytes have a significant role in coronary artery disease and cardiovascular disease(22). Azab et al. reported a relationship between increased PLR and long-term mortality in patients with myocardial infarction (23). In a different study, Ferroni et al. reported a relationship between increased PLR and risk of symptomatic venous thromboembolism (24). This study showed that PLR was significantly increased in BRVOs than the controls. However, logistic regression analysis showed that PLR was not an independent indicator of BRVO.

The limitations of the study are the small number of patients, the lack of body mass index and retrospective design of the study. New studies including more patients are needed to investigate the possible role of serum NLR and PLR levels in BRVO. However, further prospective studies are needed.

CONCLUSION

In conclusion, in this study we found that NLR and PLR were increased BRVOs than the controls. NLR may be used to estimate the risk of BRVO from haemogram parameters. Larger studies are needed to enable NLR to be used to estimate BRVO risk.

Competing interests: The Authors declares that there is no conflict of interest

Financial Disclosure: There are no financial supports.

Ethical approval: The study was carried out under the ethical principles of

the Helsinki Declaration and approved by the Sakarya University Medical School Ethics Committee.

Mahmut Atum ORCID:0000-0001-8230-8137

Isa Yuvaci ORCID:0000-0003-0694-9009

Selcuk Yaylaci ORCID:0000-0002-6768-7973

Ahmed Bilal Genc ORCID:0000-0002-1607-6355

Turgay Ucak ORCID:0000-0002-4977-4942

Erdinc Bozkurt ORCID:0000-0002-5570-799X

Gursoy Alagoz ORCID:0000-0002-7614-5690

REFERENCES

1. Wong TY, Scott IU. Retinal vein occlusion. *N Engl J Med* 2010;363:2135–44.
2. Rogers S, McIntosh RL, Cheung N, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. *Ophthalmology* 2010;117:313–9.
3. Hayreh SS, Zimmerman MB, Podhajsky P. Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics. *Am J Ophthalmol* 1994;117:429–41.
4. Koizumi H, Ferrara DC, Bruè C, et al. Central retinal vein occlusion case-control study. *Am J Ophthalmol* 2007;144:858–63.
5. The Eye Disease Case-Control Study Group. Risk factors for central retinal vein occlusion the eye disease case-control study group. *Arch Ophthalmol* 1996;114(5):545–554.
6. Jaulim A, Ahmed B, Khanam T, et al. Branch retinal vein occlusion: epidemiology, pathogenesis, risk factors, clinical features, diagnosis, and complications. An update of the literature. *Retina* 2013;33(5):901–910.
7. Deobhakta A, Chang LK. Inflammation in retinal vein occlusion. *Int J Inflam* 2013;1–6.
8. Ross R. Atherosclerosis-an inflammatory disease. *N Engl J Med*. 1999;340:115–26.
9. Tamhane UU, Aneja S, Montgomery D, et al. Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome *Am J Cardiol* 2008;102:653–7.
10. Akdag S, Akyol A, Asker M, et al. Platelet-to-lymphocyte ratio may predict the severity of calcific aortic stenosis. *Med Sci Monit* 2015;21:3395.
11. Azab B, Daoud J, Naeem FB, et al. Neutrophil-to-Lymphocyte Ratio as a Predictor of Worsening Renal Function in Diabetic Patients (3-Year Follow-Up Study). *Ren Fail* 2012;34:571–6.
12. Ryu HJ, Lee MK, Lee KH, et al. Mean platelet volume is associated with Behcet's disease activity. *Ann Rheum Dis* 2014;73:996.
13. Rehak J, Rehak M. Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities. *Curr Eye Res* 2008;33:111–31.
14. Neumann FJ, Ott I, Marx N, et al. Effect of human recombinant interleukin-6 and interleukin-8 on monocyte procoagulant activity. *Arterioscler Thromb Vasc Biol* 1997;17:3399–405.
15. van der Poll T, Büller HR, ten Cate H, et al. Activation of coagulation after administration of tumor necrosis factor to normal subjects. *N Engl J Med* 1990;322:1622–17.
16. Ulfhammer E, Larsson P, Karlsson L, et al. TNF α mediated suppression of tissue type plasminogen activator expression in vascular endothelial cells is NF κ B and p38 MAPK dependent. *J Thromb Haemost* 2006;4:1781–9.
17. Noma H, Funatsu H, Mimura T, et al. Pigment epithelium-derived factor and vascular endothelial growth factor in branch retinal vein occlusion with macular edema. *Graefes Arch Clin Exp Ophthalmol* 2010;248:1559–65.
18. Zahorec R. Ratio of neutrophil to lymphocyte counts rapid and simple parameter of systemic inflammation and stress in critically ill. *Bratisl Lek Listy* 2001;102:5–14.
19. Gokhan S, Ozhasenekler A, Durgun HM, et al. Neutrophil lymphocyte ratios in stroke subtypes and transient ischemic attack. *Eur Rev Med Pharmacol Sci* 2013;17:653–7.
20. Bhat TM, Afari ME, Garcia LA. Neutrophil lymphocyte ratio in peripheral vascular disease: a review. *Expert Rev Cardiovasc Ther* 2016;14:871–5.
21. Dursun A, Ozturk S, Yucel H, et al. Association of neutrophil/lymphocyte ratio and retinal vein occlusion. *Eur J Ophthalmol* 2015;25(4):343–346.
22. Kurtul A, Yarlioglu M, Murat SN, et al. Usefulness of the platelet-to-lymphocyte ratio in predicting angiographic reflow after primary percutaneous coronary intervention in patients with acute ST segment elevation myocardial infarction. *Am J Cardiol* 2014;114:342–7.
23. Azab B, Shah N, Akerman M, et al. Value of platelet/lymphocyte ratio as a predictor of all-cause mortality after non-ST elevation myocardial infarction. *J Thromb Thrombolysis* 2012;34:326–34.
24. Ferroni P, Riondino S, Formica V, et al. Venous thromboembolism risk prediction in ambulatory cancer patients: clinical significance of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio. *Int J Cancer* 2015;136:1234–40.